Ria R - Search Results

1

Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype.

Scarpa R, Pulvirenti F, Pecoraro A, Vultaggio A, Marasco C, Ria R, Altinier S, Compagno N, Firinu D, Plebani M, De Carli M, Matucci A, Vianello F, Vacca A, Spadaro G, Quinti I, Agostini C, Milito C, Cinetto F. Scarpa R, et al. Among authors: ria r. Front Immunol. 2020 Mar 31;11:319. doi: 10.3389/fimmu.2020.00319. eCollection 2020. Front Immunol. 2020. PMID: 32296413 Free PMC article.

2

Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression.

Vacca A, Ribatti D, Ria R, Pellegrino A, Bruno M, Merchionne F, Dammacco F. Vacca A, et al. Among authors: ria r. Dev Immunol. 2000;7(2-4):77-88. doi: 10.1155/2000/74372. Dev Immunol. 2000. PMID: 11097203 Free PMC article.

3

Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma.

Vacca A, Ribatti D, Roccaro AM, Ria R, Palermo L, Dammacco F. Vacca A, et al. Among authors: ria r. Acta Haematol. 2001;106(4):162-9. doi: 10.1159/000046612. Acta Haematol. 2001. PMID: 11815713 Review.

4

Docetaxel versus paclitaxel for antiangiogenesis.

Vacca A, Ribatti D, Iurlaro M, Merchionne F, Nico B, Ria R, Dammacco F. Vacca A, et al. Among authors: ria r. J Hematother Stem Cell Res. 2002 Feb;11(1):103-18. doi: 10.1089/152581602753448577. J Hematother Stem Cell Res. 2002. PMID: 11847007

5

Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma.

Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F. Ria R, et al. Haematologica. 2002 Aug;87(8):836-45. Haematologica. 2002. PMID: 12161360

6

Cross-talk between hematopoiesis and angiogenesis signaling pathways.

Ribatti D, Vacca A, Nico B, Ria R, Dammacco F. Ribatti D, et al. Among authors: ria r. Curr Mol Med. 2002 Sep;2(6):537-43. doi: 10.2174/1566524023362195. Curr Mol Med. 2002. PMID: 12243246 Review.

7

A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.

Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F, Dammacco F. Vacca A, et al. Among authors: ria r. Haematologica. 2003 Feb;88(2):176-85. Haematologica. 2003. PMID: 12604407

8

Vascular endothelial growth factor and its receptors in multiple myeloma.

Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Ria R, et al. Leukemia. 2003 Oct;17(10):1961-6. doi: 10.1038/sj.leu.2403076. Leukemia. 2003. PMID: 14513045 Review.

9

Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma.

Ria R, Falzetti F, Ballanti S, Minelli O, Di Ianni M, Cimminiello M, Vacca A, Dammacco F, Martelli MF, Tabilio A. Ria R, et al. Hematol J. 2004;5(2):118-22. doi: 10.1038/sj.thj.6200369. Hematol J. 2004. PMID: 15048061

10

Serum levels of angiogenic cytokines decrease after antineoplastic radiotherapy.

Ria R, Portaluri M, Russo F, Cirulli T, Di Pietro G, Bambace S, Cucci F, Romano T, Vacca A, Dammacco F. Ria R, et al. Cancer Lett. 2004 Dec 8;216(1):103-7. doi: 10.1016/j.canlet.2004.05.022. Cancer Lett. 2004. PMID: 15500953

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

161 results

Search Page